IMR Press / EJGO / Volume 42 / Issue 6 / DOI: 10.31083/j.ejgo4206163
Open Access Original Research
Real-world clinical practice patterns and outcomes for advanced ovarian cancer in Spain (GEICO-42-R study)
Show Less
1 Servicio de Oncología Médica, Hospital Universitario La Paz-IdiPAZ, Universidad Autónoma de Madrid (UAM), 28049 Madrid, Spain
2 Servicio de Oncología Médica, Hospital Universitari i Politècnic La Fe, 46026 Valencia, Spain
3 Servicio de Oncología Médica, Consorcio Hospitalario Provincial de Castellón, 12006 Castellón, Spain
4 Servicio de Oncología Médica, Hospital Universitario Son Llàtzer, 07198 Palma de Mallorca, Spain
5 Servicio de Oncología Médica, Hospital Universitario 12 de Octubre, 28041 Madrid, Spain
6 Servicio de Oncología Médica, Hospital Universitario Clínico San Carlos, 28040 Madrid, Spain
7 Servicio de Oncología Médica, Hospital Universitario Reina Sofía, Universidad de Córdoba (UCO), 14014 Córdoba, Spain
8 Unidad de Ensayos Clínicos, Fundación Investigación Clínica del IVO (FINCIVO), 46009 Valencia, Spain
9 MSD Spain, Calle Josefa Valcárcel, 38, 20027 Madrid, Spain
10 Departamento de Oncología, Clínica Universidad de Navarra, 28027 Madrid, Spain
Eur. J. Gynaecol. Oncol. 2021 , 42(6), 1116–1123;
Submitted: 22 September 2021 | Revised: 15 October 2021 | Accepted: 19 October 2021 | Published: 15 December 2021
Copyright: © 2021 The Author(s). Published by IMR Press.
This is an open access article under the CC BY 4.0 license (

Objective: To assess epidemiological, pathological and clinical characteristics, therapeutic management patterns and outcomes in the management of advanced ovarian cancer (AOC) in clinical practice. Methods: Multicenter, retrospective, epidemiological, observational real-world study reviewing clinical records from 277 patients diagnosed with AOC between January 2008 and December 2010 who were treated and followed in 31 Spanish hospitals belonging to the Spanish Ovarian Cancer Research Group (GEICO). Survival curves were estimated by Kaplan–Meier and differences analyzed by the log-rank test. Results: Median age at diagnosis was 62 years (range 26–96), 62% of patients had a high-grade serous carcinoma, and 64% and 21% of patients had stage IIIC and stage IV disease, respectively. Overall, 46% of patients underwent primary debulking surgery (PDS), with complete cytoreduction in 63% of procedures, and 34% underwent interval debulking surgery, with complete cytoreduction in 71% of them. Overall, 96% of patients received at least one cycle of front-line chemotherapy. Recurrence occurred in 77% of patients, and 90% of them (69% of total) received a second-line chemotherapy. Median progression-free survival (PFS) was 14 months (95% CI: 13–17) and median overall survival (OS) was 41 months (95% CI: 34–49). PDS and complete cytoreduction had a statistically significant correlation with PFS and OS. Conclusions: This retrospective study provides real-world data of clinical characteristics, therapeutic management, and outcomes in Spanish AOC patients. Primary debulking surgery and complete cytoreduction were favorable prognostic factors in this series.

Ovarian cancer
Real-world data
Primary debulking surgery
Complete cytoreduction
Fig. 1.
Back to top